UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
‘Body fluid management using BCM improves kidney function’
“BCM (Body Composition Monitoring) can decide the way to manage fluid for d...
by Park Gi-taek
|
2017-09-12 08:26
라인
Healthcare benefits for immune checkpoint inhibitor Tecentrqi, unclear
Roche’s immune checkpoint inhibitor Tecentriq (Atezolizumab) might have a d...
by Park Gi-taek
|
2017-08-30 10:17
라인
When can we hear about the conquest of liver cancer?
Liver cancer, one of the four deadliest cancers in Korea, is called a "sile...
by Park Gi-taek
|
2017-08-29 07:00
라인
‘Let's protect patients until complete cure of hepatitis B comes’
"In the next 15 to 20 years, we will be able to cure chronic hepatitis B co...
by Park Gi-taek
|
2017-08-28 10:46
라인
Drugmakers cut entertainment expense due to anticorruption law
Almost a year after the Act on Prohibiting Illegal Solicitation, or “Kim Yo...
by Park Gi-taek
|
2017-08-25 16:27
라인
‘Moon Jae-in care’ keeps industry busy weighing bottom lines
After President Moon Jae-in announced a policy to drastically expand health...
by Park Gi-taek
|
2017-08-11 13:42
라인
New osteoporosis therapy causes curiosity about drug price
Ten years have passed since Amgen’s “Prolia,” the so-called first biologica...
by Park Gi-taek
|
2017-08-07 14:42
라인
‘Neither handouts nor patient complaints give insurance benefits to expensive drugs’
The countdown has begun to provide insurance benefits for the controversial...
by Park Gi-taek
|
2017-07-24 20:28
라인
CEOs of foreign pharmaceuticals don't seem to regard Korean employees as colleagues
In Korea, most people perceive multinational companies as “good workplaces....
by Park Gi-taek
|
2017-07-13 18:20
라인
Castleman’s disease patients suffer from high drug prices
Recently, some therapies for a small number of patients, including Ibrance ...
by Park Gi-taek
|
2017-07-11 17:00
라인
First patient resistant to Viread found in Korea
A Korean doctor has found patients who showed resistance to Viread (compoun...
by Park Gi-taek
|
2017-06-26 13:40
라인
Is personalized cancer treatment using NGS unavailable in Korea?
Is Korea still a long way from personalized cancer treatment using next gen...
by Park Gi-taek
|
2017-06-22 18:19
라인
‘Korean version of NOAC guidelines may come out before long’
Since the introduction of Non-Vitamin K Antagonist Oral Anticoagulant (NOAC...
by Park Gi-taek
|
2017-06-20 17:52
라인
‘Early diagnosis necessary for treating rare Gaucher's disease’
There are about 7,000 rare diseases found worldwide, but a fraction of them...
by Park Gi-taek
|
2017-06-19 20:22
라인
Introduction of DAA changed treatment of Hepatitis C
Since the approval of the combination therapy Daklinza-Sunvepra (Daksun the...
by Park Gi-taek
|
2017-06-07 16:43
라인
Gilead’s new hepatitis B therapy in controversy due to side effects
Could it be that Gilead’s new hepatitis B medicine Vemlidy (compound tenofo...
by Park Gi-taek
|
2017-05-31 17:04
라인
Gilead Sciences keeps on rolling in Korea: Why?
When the news spread six years ago that Gilead Sciences길리어드 would enter the...
by Park Gi-taek
|
2017-05-11 14:52
라인
Can Jardiance threaten Forxiga's dominance in treating diabetes?
Korean regulators have officially recognized the effect of SGLT-2 (sodiumgl...
by Park Gi-taek
|
2017-05-04 13:30
라인
‘We must move beyond completely curing Hepatitis C to eradicating it’
From the end of 2015 to 2016, mass infections of hepatitis C occurred at th...
by Park Gi-taek
|
2017-04-18 14:47
라인
Will post-mass infection anti-HCV measures prove to be sufficient?
From the end of 2015 to 2016, mass infections of hepatitis C occurred at th...
by Park Gi-taek
|
2017-04-17 16:49
-
1
2
3
4
5
6
7
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top